StockpollyBeta
Get App
Popularity #4,081Earnings in 2d
ENLV · NASDAQ · Biotechnology

Enlivex (ENLV)

Develops Allocetra for knee osteoarthritis and manages a RAIN-centered digital-asset treasury.

$0.6154
vs last close−0.03 (−4.80%)

  1. Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones

    GlobeNewsWire

  2. Enlivex Ltd. (ENLV) Upgraded to Buy: Here's Why

    Zacks Investment Research

  3. Enlivex Ltd. (ENLV) Loses 31.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

    Zacks Investment Research

  4. Enlivex Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Allocetra™ in Age-Related Knee Osteoarthritis

    GlobeNewsWire

  5. Enlivex Announces 1-for-15 Reverse Stock Split Effective July 9, 2026

    GlobeNewsWire

  6. Enlivex Announces Issuance of Australian Patent Covering the Use of Allocetra™ in Patients with Osteoarthritis

    GlobeNewsWire

  7. Allocetra Shows Durable 6-Month Efficacy in Knee Osteoarthritis Phase IIa Trial; Oral Presentation at EULAR 2026

    GlobeNewsWire

  8. Enlivex Announces Dosing Of First Patient In The United States As Part Of Its Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis

    GlobeNewsWire

  9. Enlivex to Present Phase IIa 3-month and 6-month Data of Allocetra at OARSI 2026 World Congress

    GlobeNewsWire

  10. Enlivex Announces Second Regulatory Approval for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis

    Globe News Wire

  11. Enlivex Announces Second Regulatory Approval for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis

    GlobeNewsWire

  12. Enlivex Therapeutics Q4 Earnings Call Highlights

    Defense World

  13. Enlivex Reports Full-Year 2025 Results: Profit (Net Income) of $1.23 Billion and Diluted Earnings Per Share (EPS) of $25.48

    GlobeNewsWire

  14. Quality Longevity Company Enlivex Receives Investigational New Drug (IND) Clearance from the FDA for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis

    GlobeNewsWire

  15. Enlivex Appoints former Italy Prime Minister Matteo Renzi to Board of Directors

    PRNewsWire

  16. Enlivex Announces Positive 6-Month Topline Data –Demonstrating Durable and Persistent Pain Reduction and Improved Function in Primary Age-Related Patients with Moderate to Severe Knee Osteoarthritis

    GlobeNewsWire

  17. Enlivex CEO Issues Letter to Shareholders Outlining Strategic Roadmap Following Positive Phase IIa Allocetra™ Results

    GlobeNewsWire

  18. Enlivex Announces Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee Osteoarthritis

    GlobeNewsWire

  19. Enlivex to Present 3-Month Topline Data from Phase IIa Moderate/Severe Knee Osteoarthritis Trial on August 18 Webinar

    GlobeNewsWire

  20. Enlivex Therapeutics to Present Clinical Data of Allocetra in Osteoarthritis at EULAR 25 European Congress of Rheumatology

    GlobeNewsWire

  21. Enlivex Selected to Present at Israeli BioMed 2025 Conference

    GlobeNewsWire

  22. Enlivex Therapeutics to Showcase Allocetra's Potential in Osteoarthritis at OARSI 2025 World Congress

    GlobeNewsWire

  23. Enlivex Announces Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis

    GlobeNewsWire

  24. Enlivex Announces the Dosing of the First Patient in a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis

    GlobeNewsWire